The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Self-assembled peptide–poloxamine nanoparticles enable in vitro and in vivo genome restoration for cystic fibrosis
Abstract
Developing safe and efficient non-viral delivery systems remains a major challenge for in vivo applications of gene therapy, especially in cystic fibrosis. Unlike conventional cationic polymers or lipids, the emerging poloxamine-based copolymers display promising in vivo gene delivery capabilities. However, poloxamines are invalid for in vitro applications and their in vivo transfection efficiency is still low compared with viral vectors. Here, we show that peptides developed by modular design approaches can spontaneously form compact and monodisperse nanoparticles with poloxamines and nucleic acids via self-assembly. Both messenger RNA and plasmid DNA expression mediated by peptide-poloxamine nanoparticles are greatly boosted in vitro and in the lungs of cystic fibrosis mice with negligible toxicity. Peptide-poloxamine nanoparticles containing integrating vectors enable successful in vitro and in vivo long-term restoration of cystic fibrosis transmembrane conductance regulator deficiency with a safe integration profile. Our dataset provides a new framework for designing non-viral gene delivery systems qualified for in vivo genetic modifications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After three-time i.t. administration, CFTR expression lasted for 18 weeks in CF mice and the level was similar to that of the wild type group.”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [45]
In the citing paper
“Meanwhile, lung pathohistological sections indicated no visible signs of inflammatory infiltrates and blood sample analysis showed a normal level of white blood cells.[45]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [45]
Citations
Cites
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Webb, A. K. (2006) · Cited by 4,369
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Elborn, J. S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00576-6 · Cited by 1,805
Cheng, S. H., Gregory, R. J., Marshall, J., Paul, S., Souza, D. W., White, G. A., O’Riordan, C. R., & Smith, A. E. (1990) · Cell · doi:10.1016/0092-8674(90)90148-8 · Cited by 1,792
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460
Schwank, G., Koo, B.-K., Sasselli, V., Dekkers, J. F., Heo, I., Demircan, T., Sasaki, N., Boymans, S., Cuppen, E., van der Ent, C. K., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.11.002 · Cited by 1,424
Therapeutic genome editing: prospects and challenges
Cox, D. B. T., Platt, R. J., & Zhang, F. (2015) · Nature Medicine · doi:10.1038/nm.3793 · Cited by 1,336
Overcoming cellular barriers for RNA therapeutics
Dowdy, S. F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3802 · Cited by 1,139
A functional CFTR assay using primary cystic fibrosis intestinal organoids
Dekkers, J. F., Wiegerinck, C. L., de Jonge, H. R., Bronsveld, I., Janssens, H. M., de Winter-de Groot, K. M., Brandsma, A. M., de Jong, N. W. M., Bijvelds, M. J. C., Scholte, B. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3201 · Cited by 999
Cited by
Sorted by citations
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs
Lokugamage, M. P., Vanover, D. A., Beyersdorf, J. P., Hatit, M. Z. C., Rotolo, L., Echeverri, E. S., Peck, H. E., Ni, H., Yoon, J., Kim, Y., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00786-x · Cited by 525
Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza
Abbott, T. R., Dhamdhere, G. R., Liu, Y., Lin, X., Goudy, L., Zeng, L., Chemparathy, A., Chmura, S. A., Heaton, N. S., Debs, R. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.020 · Cited by 509
Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination
Suberi, A., Grun, M. K., Mao, T., Israelow, B., Reschke, M., Grundler, J., Akhtar, L., Lee, T., Shin, K., Piotrowski-Daspit, A. S., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq0603 · Cited by 190
Loughrey, D., & Dahlman, J. E. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00601 · Cited by 173
Metadata
- Authors
- Guan, S., Munder, A., Hedtfeld, S., Braubach, P., Glage, S., Zhang, L., Lienenklaus, S., Schultze, A., Hasenpusch, G., Garrels, W., Stanke, F., Miskey, C., Johler, S. M., Kumar, Y., Tümmler, B., Rudolph, C., Ivics, Z., & Rosenecker, J.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- Medizinische Hochschule Hannover (DE)
- Ethris (Germany) (DE)
- Paul Ehrlich Institut (DE)
- GATC Biotech (Germany) (DE)
- Corresponding author
- Rosenecker, Joseph
- ORCID
- Venue
- Nature Nanotechnology
- Published
- 2019-01-28
- Volume
- 14
- Issue
- 3
- Pages
- 287-297
- ISSN
- 1748-3387 (ISSN-L)
- 1748-3395
- OpenAlex
- W2914518223
- Cited by
- 130
- References
- 51
- Citations by year
- 2026: 11 · 2025: 21 · 2024: 19 · 2023: 19 · 2022: 21 · 2021: 13 · 2020: 16 · 2019: 10
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Nanotechnology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bundesministerium für Bildung und Forschung
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Keywords
- cystic fibrosis, poloxamine, self-assembly, non-viral gene delivery, gene therapy, CFTR, plasmid transfection, mRNA delivery, integrating vectors, in vivo transfection, lung gene delivery
- MeSH terms
- Amino Acid Sequence, Animals, Cell Line, Cystic Fibrosis, Ethylenediamines, Gene Expression Regulation, Humans, Luciferases, Peptides, RNA, Messenger, Genome, Genes, Reporter, Cystic Fibrosis Transmembrane Conductance Regulator, Transgenes, Mice, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
